JP4489303B2 - ニューロトロフィンおよびそのアナログを使用する、胃腸の低運動性障害の処置方法 - Google Patents

ニューロトロフィンおよびそのアナログを使用する、胃腸の低運動性障害の処置方法 Download PDF

Info

Publication number
JP4489303B2
JP4489303B2 JP2000593329A JP2000593329A JP4489303B2 JP 4489303 B2 JP4489303 B2 JP 4489303B2 JP 2000593329 A JP2000593329 A JP 2000593329A JP 2000593329 A JP2000593329 A JP 2000593329A JP 4489303 B2 JP4489303 B2 JP 4489303B2
Authority
JP
Japan
Prior art keywords
composition
neurotrophin
constipation
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000593329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534479A (ja
JP2002534479A5 (enExample
Inventor
ジェシー エム． セダーバウム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2002534479A publication Critical patent/JP2002534479A/ja
Publication of JP2002534479A5 publication Critical patent/JP2002534479A5/ja
Application granted granted Critical
Publication of JP4489303B2 publication Critical patent/JP4489303B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2000593329A 1999-01-15 2000-01-11 ニューロトロフィンおよびそのアナログを使用する、胃腸の低運動性障害の処置方法 Expired - Lifetime JP4489303B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/232,171 1999-01-15
US09/232,171 US6656474B1 (en) 1999-01-15 1999-01-15 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
PCT/US2000/000682 WO2000041719A1 (en) 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Publications (3)

Publication Number Publication Date
JP2002534479A JP2002534479A (ja) 2002-10-15
JP2002534479A5 JP2002534479A5 (enExample) 2007-02-22
JP4489303B2 true JP4489303B2 (ja) 2010-06-23

Family

ID=22872143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000593329A Expired - Lifetime JP4489303B2 (ja) 1999-01-15 2000-01-11 ニューロトロフィンおよびそのアナログを使用する、胃腸の低運動性障害の処置方法

Country Status (13)

Country Link
US (1) US6656474B1 (enExample)
EP (1) EP1146899B1 (enExample)
JP (1) JP4489303B2 (enExample)
AT (1) ATE345811T1 (enExample)
AU (1) AU775860B2 (enExample)
CA (1) CA2360252C (enExample)
DE (1) DE60031951D1 (enExample)
IL (2) IL144315A0 (enExample)
NO (1) NO329488B1 (enExample)
NZ (1) NZ512968A (enExample)
TR (2) TR200102767T2 (enExample)
WO (1) WO2000041719A1 (enExample)
ZA (1) ZA200105799B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MXPA02012602A (es) * 2000-06-22 2003-05-14 Genentech Inc Anticuerpos monoclonales agonistas anti-trk-c.
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
JP2006520806A (ja) * 2003-03-20 2006-09-14 ライナット ニューロサイエンス コーポレイション タキソール誘導性腸障害を処置する方法
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US5962404A (en) * 1989-08-28 1999-10-05 Yeda Research & Development Co., Ltd. Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
AU4920893A (en) * 1992-09-14 1994-04-12 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
CA2188017C (en) * 1994-04-25 2010-09-28 Joffre Baker Cardiotrophin and uses therefor
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6211142B1 (en) 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP3540912B2 (ja) * 1997-03-28 2004-07-07 京セラ株式会社 釣糸用ガイド部材
WO1998049308A1 (en) 1997-04-25 1998-11-05 Genentech, Inc. Ngf variants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor

Also Published As

Publication number Publication date
NZ512968A (en) 2003-09-26
TR200201875T2 (tr) 2002-09-23
NO20013493D0 (no) 2001-07-13
CA2360252C (en) 2010-11-02
ZA200105799B (en) 2002-01-24
CA2360252A1 (en) 2000-07-20
IL144315A (en) 2008-08-07
NO20013493L (no) 2001-09-17
IL144315A0 (en) 2002-05-23
EP1146899A1 (en) 2001-10-24
JP2002534479A (ja) 2002-10-15
AU2963600A (en) 2000-08-01
TR200102767T2 (tr) 2002-04-22
EP1146899B1 (en) 2006-11-22
DE60031951D1 (de) 2007-01-04
EP1146899A4 (en) 2003-03-05
ATE345811T1 (de) 2006-12-15
NO329488B1 (no) 2010-10-25
AU775860B2 (en) 2004-08-19
US6656474B1 (en) 2003-12-02
WO2000041719A9 (en) 2001-08-30
WO2000041719A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
JP4489303B2 (ja) ニューロトロフィンおよびそのアナログを使用する、胃腸の低運動性障害の処置方法
JP7723649B2 (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用方法
ES2304811T3 (es) Fragmentos del factor de crecimiento de tejido conjuntivo.
CN1723039B (zh) 抗神经生长因子抗体拮抗剂在制备治疗手术后疼痛的药物中的应用
ES2363162T3 (es) Composicones y procedimientos para el tratamiento de trastornos fibróticos.
US5824303A (en) Eck receptor ligands
EP4358995B1 (en) A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
EA013506B1 (ru) Антитело к il-23 и его применение
EA011583B1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
JPH10505358A (ja) クロストリジウム・ディフィシル関連疾患の治療処置
CZ291047B6 (cs) Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
US20030211967A1 (en) Method for selectively inhibiting ghrelin action
WO2005000194A2 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
JP2008500285A (ja) 塩ホメオスタシス及び／又は水分ホメオスタシスに伴う疾患のための治療薬及び診断薬としての、プロウログアニリン、及びそれに由来する合成類似体又はタンパク質分解切断産物
WO1998016245A1 (fr) Procede de determination d'un auto-anticorps
TW202142256A (zh) 一種治療脊髓性肌萎縮症的方法和藥物
EA006744B1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
NO320773B1 (no) Isolert polypeptid og vektor omfattende dette, artrittogent peptid av polypeptidet og sammensetning omfattende dette for forebyggelse og behandling av reumatoid artritt.
KR20230159463A (ko) Cd3 및 cd19에 대해 이중 특이성을 갖는 페길화된 t 세포 인게이저
KR20230052929A (ko) 종양 치료 방법 및 약물
JP4149713B2 (ja) 感染症治療剤
JP2005506833A5 (enExample)
KR101917419B1 (ko) Ｃｒｉｆ１을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물
US20100196376A1 (en) Method for reducing allergen-induced airway hyperresponsiveness
US20010046955A1 (en) Method for reducing allergen-induced airway hyperresponsiveness

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100326

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100331

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130409

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4489303

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130409

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140409

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term